Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects

Journal of Drug Targeting

Volumn 13, Issue 5, 2005, Pages 325-335

  Schnyder, Anita ^a   Krähenbühl, Stephan ^a   Drewe, Jürgen ^a   Huwyler, Jörg ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Biotinylated immunoliposomes; Brain targeting; OX26 monoclonal antibody; Transferrin receptor

Indexed keywords

BIOTIN; DAUNORUBICIN; GLYCOPROTEIN P; IMMUNOGLOBULIN G2A; IMMUNOLIPOSOME; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; STREPTAVIDIN; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CAPILLARY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DRUG UPTAKE; ENDOTHELIUM CELL; IN VITRO STUDY; KIDNEY; LIVER; MALE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; TISSUE DISTRIBUTION;

ALGORITHMS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BIOTIN; CELLS, CULTURED; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; IMMUNOCHEMISTRY; IMMUNOGLOBULIN G; LIPOSOMES; MALE; RATS; RATS, WISTAR; RHODAMINES; TISSUE DISTRIBUTION;

EID: 24644485229     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860500206674     Document Type: Article

References (61)

1. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. 1995. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1237:99-108.
2. Begley DJ, Lechardeur D, Chen ZD, Rollinson C, Bardoul M, Roux F, Scherman D, Abbott NJ. 1996. Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4. J Neurochem 67:988-995.
3. Bendas G. 2001. Immunoliposomes: A promising approach to targeting cancer therapy. Bio Drugs 15:215-224.
4. Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U. 1999. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm 181:79-93.
5. Bickel U, Kang YS, Yoshikawa T, Pardridge WM. 1994. In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 42:1493-1497.
6. Bittner B, Bravo González RC, Walter I, Kapps M, Huwyler J. 2003. Impact of solutol HS15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. Biopharm Drug Dispos 24:173-181.
7. Broadwell RD, Baker-Cairns BJ, Friden PM, Oliver C, Villegas JC. 1996. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp Neurol 142:47-65.
8. Cerletti A, Drewe J, Fricker G, Eberle AN, Huwyler J. 2000. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 8:435-447.
9. Collins D, Maxfield F, Huang L. 1989. Immunoliposomes with different acid sensitivities as probes for the cellular endocytic pathway. Biochim Biophys Acta 987:47-55.
10. Connor J, Huang L. 1985. Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes. J Cell Biol 101:582-589.
11. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
12. Dollery C. 1999. Daunorubicin (hydrochloride). In: Dollery C, editor. Therapeutic drugs. London: Churchill Livingstone. p D18-D23.
13. Endicott JA, Ling V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171.
14. Eytan GD, Kuchel PW. 1999. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int Rev Cytol 190:175-250.
15. Frank MM. 1993. The reticuloendothelial system and bloodstream clearance. J Lab Clin Med 122:487-488.
16. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. 1991. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 88:4771-4775.
17. Friden PM, Olson TS, Obar R, Walus LR, Putney SD. 1996. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor. J Pharmacol Exp Ther 278:1491-1498.
18. Gonzalez M, Bagatolli LA, Echabe I, Arrondo JL, Argarana CE, Cantor CR, Fidelio GD. 1997. Interaction of biotin with streptavidin. Thermostability and conformational changes upon binding. J Biol Chem 272:11194-11288.
19. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. 2000. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6:1949-1957.
20. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. 1995. Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1239:133-144.
21. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Ito N, Nohga K, Nagaike K. 2004. Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes. Hybrid Hybridomics 23:109-120.
22. Huwyler J, Wu D, Pardridge WM. 1996. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169.
23. Huwyler J, Yang J, Pardridge WM. 1997. Receptor mediated delivery of daunomycin using immunoliposomes: Pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther 282:1541-1546.
24. Huwyler J, Froidevaux S, Roux F, Eberle AN. 1999. Characterization of the transferrin receptor in an immortalized cell line of rat brain endothelial cells, RBE4. J Recept Signal Transduct Res 19:729-739.
25. Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. 2002. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 10:73-79.
26. Hymes J, Fleischhauer K, Wolf B. 1997. Biotinidase in serum and tissues. Methods Enzymol 279:422-434.
27. Jefferies WA, Brandon MR, Williams AF, Hunt SV. 1985. Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology 54:333-341.
28. Juranka PF, Zastawny RL, Ling V. 1989. P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583-2592.
29. Kang YS, Bickel U, Pardridge WM. 1994. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metab Dispos 22:99-105.
30. Kawasaki T, Carmichael FJ, Saldivia V, Roldan L, Orrego H. 1990. Relationship between portal venous and hepatic arterial blood flows: Spectrum of response. Am J Physiol Gastrointest Liver Physiol 259:G1010-G1018.
31. Lasic DD, Papahadjopoulos D. 1995. Liposomes revisited. Science. 267:1275-1276.
32. Lee HJ, Pardridge WM. 2000. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). J Drug Target 8:413-424.
33. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. 2003. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updates 6:271-279.
34. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. 1995. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1234:74-80.
35. Mastrobattista E, Koning GA, Storm G. 1999. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 40:103-127.
36. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H et al. 2004. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15:517-525.
37. Mori A, Klibanov AL, Torchilin VP, Huang L. 1991. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett 284:263-266.
38. Nakano S, Matsukado K, Black KL. 1996. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 56:4027-4031.
39. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. 1991. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464.
40. Pardridge WM. 1995a. Transport of small molecules through the blood-brain barrier: Biology and methodology. Adv Drug Deliv Rev 15:5-36.
41. Pardridge WM. 1995b. Vector-mediated peptide drug delivery to the brain. Adv Drug Deliv Rev 15:109-146.
42. Pardridge WM, Buciak JL, Friden PM. 1991. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier. J Pharmacol Exp Ther 259:66-70.
43. Parente RA, Nir S, Szoka Jr, FC. 1988. pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide. J Biol Chem 263:4724-4730.
44. Roninson IB. 1992. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43:95-102.
45. Roux F, Durieu-Trautmann O, Chaverot N, Claire M, Mailly P, Bourre JM, Strosberg AD, Couraud PO. 1994. Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol 159:101-113.
46. Schnyder A, Huwyler J. 2005. Drug transport to brain with targeted liposomes. NeuroRx 2:99-107.
47. Schnyder A, Krahenbuhl S, Török M, Drewe J, Huwyler J. 2004. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 377:61-67.
48. Shahinian S, Silvius JR. 1995. A novel strategy affords high-yield coupling of antibody Fab′ fragments to liposomes. Biochim Biophys Acta 1239:157-167.
49. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC. 2004. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56:947-965.
50. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
51. Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y. 1997. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor. Br J Cancer 76:83-89.
52. Torchilin VP. 1994. Immunoliposomes and PEGylated immunoliposomes: Possible use for targeted delivery of imaging agents. Immunomethods 4:244-258.
53. Tycko B, Keith CH, Maxfield FR. 1983. Rapid acidification of endocytic vesicles containing asialoglycoprotein in cells of a human hepatoma line. J Cell Biol 97:1762-1776.
54. Vogel K, Wang S, Lee RJ, Chmielewski J, Low PS. 1996. Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J Am Chem Soc 118:1581-1586.
55. Wei RD, Kou DH, Hoo SL. 1971. Dissociation of avidin-biotin complex in vivo. Experientia 27:366-368.
56. Wu D, Boado RJ, Pardridge WM. 1996. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther 276:206-211.
57. Yoshikawa T, Pardridge WM. 1992. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther 263:897-903.
58. Zhang Y, Zhu C, Pardridge WM. 2002. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 6:67-72.
59. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. 2003a. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 14:1-12.
60. Zhang Y, Schlachetzki F, Pardridge WM. 2003b. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7:11-18.
61. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. 2004. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10:3667-3677.